A Randomized, Double-Blind, Histamine-Controlled, Phase 3 Study to Determine the Safety and Efficacy of Bee Venom in the Treatment of Knee Osteoarthritis
Persons With Mild to Moderate Knee Osteoarthritis
Enrolment: 40 · Results not recorded
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Persons With Mild to Moderate Knee Osteoarthritis
Enrolment: 40 · Results not recorded
Chronic Low Back Pain
Enrolment: 54 · Results not recorded
Healthy Volunteers
Enrolment: 20 · Results not recorded
Skin Health
Enrolment: 40 · Results not recorded
Other Disorders of Muscle in Diseases Classified Elsewhere
Enrolment: 79 · Results not recorded
Sciatica Due to Intervertebral Disc Disorder · Intervertebral Disc Displacement · Sciatica · Sciatic Radiculopathy
Enrolment: 1000 · Results not recorded
Knee Osteoarthritis · Osteoarthritis
Enrolment: 30 · Results not recorded
Apitoxin · Bee Venom Therapy · Management · Aphthous Ulceration
Enrolment: 60 · Results not recorded
Lumbar Spinal Stenosis
Enrolment: 38 · Results not recorded
Lumbar Intervertebral Disc Displacement · Cervical Intervertebral Disc Displacement
Enrolment: 505 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Cisplatin-induced acute kidney injury (cisplatin 15 mg/kg)
Melittin inhibited the cisplatin-induced rise in creatinine and blood urea nitrogen, significantly decreased M1 marker expression and increased M2 markers, and substantially reduced tubular necrosis.
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.